Search Results

Our upcoming Employee Wellbeing Conference 2025 brings you everything that you need to know about Saudi Arabia’s focus on the latest initiatives that will help to transform your organisation’s wellbeing strategies

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile marred the results.

AL Ideathon is an idea-sharing event designed to encourage creativity and innovation in the pharma, healthcare, and life sciences sectors. It provides a platform where participants can present their ideas to address real-world challenges faced by the industry. Last year, AL Ideathon received over 544 ideas, and prizes worth ₹10 lakhs were distributed to the winners. The event was a resounding success, with participants gaining recognition and many ideas being highlighted on our platform for their originality and relevance. The purpose of AL Ideathon is simple - great ideas should not remain on paper. By creating a space where professionals and innovators can collaborate. Whether it is a new approach to quality management, smarter use of digital systems, or ways to reduce manual effort in regulated environments, AL Ideathon values ideas that bring measurable impact. Building on the success of last year, this year’s AL Ideathon will be held on 27th September in Mumbai. The event once again invites professionals and innovators to share their perspectives on improving processes, compliance, efficiency, and patient outcomes. Every idea, whether simple or detailed, has the potential to spark meaningful discussions and inspire industry-wide conversations. Have an idea worth sharing? Submit your entry today and let your vision be heard at AL Ideathon 2025.

A new study in JAMA contradicts a series of statements made by HHS Secretary Robert F. Kennedy Jr. that paint vaccine advisory committees at the CDC and FDA as hopelessly corrupt.

The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term clinical data for the asset.

Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer.

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its bifunctional small-molecule drugs.

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.